Background
==========

Epstein Barr virus (EBV) is a tumor virus associated with multiple human malignancies of lymphoid or epithelial origin, including Burkitt lymphoma (BL), Hodgkin disease (HD), nasopharyngeal carcinoma (NPC), gastric carcinoma (GsCa), nasal NK-lymphoma and posttransplant lymphoproliferative disease (PTLD), with more than 90% of adults infected in the world \[[@B1],[@B2]\]. EBV has two types of infection in cells: latent or lytic. It persists in the human host as lifelong latent infection, which requires periodically reactivation of lytic genes and viral replication for maintaining its latency \[[@B3]\]. Two immediate-early (IE) proteins, BZLF1 (Zta) and BRLF1 (Rta), are essential to the switch from latent to lytic infection \[[@B4]\].

Epigenetic regulation of EBV genome is a fundamental regulatory mechanism determining different types of EBV infections in its associated tumors \[[@B5]-[@B8]\]. Several latent or lytic genes, including EBV nuclear antigens (EBNA-2, 3A, 3B, 3 C), latent membrane protein 1 (LMP1), IE antigens (Zta, Rta) and lytic cycle viral kinases, have been identified tightly controlled by the CpG methylation of various EBV promoters \[[@B1],[@B5],[@B9],[@B10]\], such as W promoter (Wp), C promoter (Cp), Q promoter (Qp), F promoter (Fp), LMP1 promoters (ED-L1 and ED-L1E promoters), Z promoter (Zp) and R promoter (Rp). The precise epigenetic regulation ensures the production of viral progeny without releasing viral antigens detectable by host immune system. Meanwhile, reactivation of viral genes from latency by demethylation agents could serve as a therapeutic strategy for EBV-associated tumors \[[@B1],[@B10]-[@B12]\].

Our previous work characterized the CpG methylation of EBV major latent promoters Qp, Fp and Cp by genomic sequencing \[[@B13],[@B14]\]. Recent studies of IE genes have been focused on the methylation-dependent binding and activation of Zta to Rp and other viral promoters \[[@B15]-[@B17]\], while the overall methylation status of Zp and Rp in tumor cells still remains unclear. Here, we studied the methylation profiles of Zp and Rp in a series of EBV-positive cell lines and primary tumors of epithelial, NK- or B-cell origin. We also evaluated the effect of demethylation agent on the reactivation of *BZLF1*and *BRLF1*in EBV-positive cell lines.

Methods
=======

Cell lines and tumor samples
----------------------------

B95-8 is an EBV-immortalized lymphoblastoid cell line. Rael, Akata, Wanyonyi (Wan), Raji, Namalwa, and AG876 are EBV-positive BL cell lines \[[@B13],[@B14]\]. SNK6 and NK-YS are EBV-positive NK-cell lymphoma cell lines \[[@B13],[@B14]\]. C666-1 is EBV-positive NPC cell line \[[@B18]\]. SNU719 and YCCEL1 (Rha, Tao, et al, unpublished) are EBV-positive gastric carcinoma cell lines \[[@B19],[@B20]\]. All cell lines were cultivated at 37°C in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 1 mmol/L glutamine, 100 U/ml penicillin and streptomycin (Invitrogen, CA). Cell lines were maintained at 37°C in cRPMI 1640. 5-aza-dC (Sigma-Aldrich, St Louis, MO) was used at different concentrations and time to treat Rael, NK-YS and C666-1 cell lines. Other cell lines were treated with 10 μmol/L 5-aza-dC (Aza, Sigma-Aldrich, St. Louis, MO) for 3 days or further treated with 100 nmol/L trichostatin A (TSA, Cayman Chemical Co., Ann Arbor, MI) for additional \~16 h as described previously \[[@B21],[@B22]\]. Archival tumor DNA samples have been previously described \[[@B21],[@B23]-[@B25]\]. The study was approved by Johns Hopkins Medicine Institutional Review Board.

Semiquantitative reverse transcription (RT)-PCR
-----------------------------------------------

Reverse transcription using random hexamer and RT-PCR using Go-Taq (Promega, Madison, WI) were performed as previously, with *GAPDH*as a control \[[@B26]\]. Sequences of primers are listed in Table [1](#T1){ref-type="table"}.

###### 

Sequences of primers used in this study

  v*p*       *Primers*   *Sequence (5\'-3\')*       *Product size*   *Annealing Temp.(°C)*   *Cycles*
  ---------- ----------- -------------------------- ---------------- ----------------------- ----------
  *RT-PCR*   *BZLF1*F    GGGAGAAGCACCTCAACCTG       255-bp           55                      35
             *BZLF1*R    TTGCTTAAACTTGGCCCGGC                                                
             *BRLF1*F    CAAACAGACGCAGATGAGGC       443-bp           55                      35
             *BRLF1*R    GCGGTGCCTATGGTGGCAGG                                                
             *BHRF1*H2   GTCAAGGTTTCGTCTGTGTG       213-bp           55                      35
             *BHRF1*H3   TTCTCTTGCTGCTAGCTCCA                                                
             *BLLF1*F    GTGGATGTGGAACTGTTTCCAG     230-bp           55                      35
             *BLLF1*R    CTGTATCCACCGCGGATGTCAC                                              
             *BART*A3    AGAGACCAGGCTGCTAAACA       232-bp           55                      35
             *BART*A4    AACCAGCTTTCCTTTCCGAG                                                
             *GAPDH*F    GATGACCTTGCCCACAGCCT       303-bp           55                      23
             *GAPDH*R    ATCTCTGCCCCCTCTGCTGA                                                
  *MSP*      Zpm1        TCGGATTTTCGTGGGTTAATC      101-bp           64                      42
             Zpm2        CGAAACTAACGTTAAAAATCCG                                              
             Zpu1        ATTTGGATTTTTGTGGGTTAATT    101-bp           62                      40
             Zpu2        CCAAAACTAACATTAAAAATCCA                                             
             Rpm1        TAGGTATTTTGGATATTCGTAC     172-bp           64                      42
             Rpm3        GATTTAATCCCAACCGCCG                                                 
             Rpu1        TGTAGGTATTTTGGATATTTGTAT   78-bp            62                      40
             Rpu2        CAAATCATTACTCCAAACTATCA                                             
  *BGS*      ZpMZP1      AAAAAACACCTAATATAAATCAAA   814-bp           62                      42
             ZpSC22      GTTAAAGAGGATTAGGTTTTTTT                                             
             RpMRP1      TCTTTTATAAACCATTAACATAAA   599-bp           60                      42
             RpMRP2      GAGATTGATAGGATTATATTGT                                              

DNA bisulfite treatment and methylation analysis
------------------------------------------------

Bisulfite modification of DNA, methylation-specific PCR (MSP), and bisulfite genomic sequencing (BGS) were carried out as described \[[@B14],[@B26]\]. Bisulfite-treated DNA was PCR amplified with strand-specific primers (for bisulfite-converted top strand of Zp and Rp) for BGS. MSP and BGS primers of Zp and Rp are listed in Table [1](#T1){ref-type="table"}.

Results
=======

Analysis of CpG sites in Z and R promoters
------------------------------------------

The two IE transcripts derived from EBV genome are shown in Figure [1A](#F1){ref-type="fig"}, *BZLF1*and *BRLF1*are located adjacent to each other on the EBV genome. *BZLF1*mRNA (\~1.0 kb) can be transcribed from both Zp and Rp, but its protein product Zta mainly derived from Zp. *BRLF1*mRNA (\~4.0 kb) is transcribed from Rp and encodes Rta. We evaluated the distribution of CpG sites and transcriptional regulatory motifs in Zp and Rp. In Zp, only few CpG sites exist in the \"ZI\" and \"ZII\" motifs, which are the critical elements for activation of Zp by binding of several transcript factors including CREB, ATF1/2, MEF2D and Smad3/Smad4. The other negative regulatory motifs in Zp, like the proximal ZV element for binding of zinc-finger E-box binding factor (ZEB), and distal elements for binding of transcription factors YY1 and E-box binding protein (E2-2), show scattered distribution of CpG sites (Figure [1B](#F1){ref-type="fig"}). In Rp, two Zta-responsive elements (RpZRE2 and RpZRE3) contain several CpG sites, mainly responsible for *BRLF1*transcription, while other regulatory elements, such as Sp1, EGR-1, contain only 1-2 CpG sites (Figure [1C](#F1){ref-type="fig"}). Thus, promoter CpG methylation of Zp and Rp may regulate *BZLF1*and *BRLF1*activation in EBV life cycle.

![**Transcription of EBV immediate-early (IE) genes**. (A) The locations of two immediate-early (IE) genes, BZLF 1 and BRLF1, the two IE promoters, Zp and Rp, are shown. (B, C) Schematic drawing of the structure of Zp and Rp including the distribution of CpG sites, transcriptional elements and the location of analyzed MSP sites and BGS region. HI: the multiply repeated sequence motif. ZI, ZII and ZIII: three positive regulatory *cis*-acting elements. ZI motifs (ZIA, ZIB, ZIC, and ZID): AT-rich sequences. ZRE: Zta-response element. Shadowed region in Zp indicates a region not methylated in any sample. Shadowed region in Rp indicates the binding site for Zta.](1471-2407-12-125-1){#F1}

Methylation status of Zp and Rp in EBV-positive cell lines of epithelial, NK- or B-cell origins
-----------------------------------------------------------------------------------------------

We then examined the expression of *BZLF1*and *BRLF1*in EBV-positive tumor cell lines. Results showed that *BZLF1*and *BRLF1*were readily expressed in EBV-positive cell lines (C666-1, YCCEL1, B95-8, and AG876), with expression of early lytic gene *BHRF1*and late lytic gene *BLLF1*also detected in these cell lines. In addition, weak expression of *BRLF1*was detected in Raji cells but without *BZLF1*(Figure [2A](#F2){ref-type="fig"}). SUN719 showed only trace expression of *BZLF1*, *BRLF1*and lytic *BHRF1*but weak expression of *BLLF1*.

![**(A, B) The expression of *BZLF1*, *BRLF1*, *BHRF1*(lytic) and *BLLF1*examined by RT-PCR, and methylation of Zp and Rp analyzed by MSP in EBV-positive cell lines**. M, methylated; U, unmethylated. (C, D) BGS analyses of Zp and Rp methylation status in Burkitt lymphoma (BL) and lymphoid (LCL) cell lines. Circles, CpG sites analyzed; row of circles, an individual promoter allele sequenced; Filled circle, methylated; empty circle, unmethylated. \"x\" circle, CpG site abolished by sequence variation or undetermined methylation status due to unconverted C in nearby CpN site.](1471-2407-12-125-2){#F2}

Next, we used methylation-specific PCR (MSP) to evaluate the promoter methylation of Zp and Rp. Primers were designed to specifically amplify a region containing the dense CpG sites in Zp and Rp. Zp and Rp methylation was detected in all EBV-positive cell lines, while unmethylated alleles were mainly seen in cell lines expressing *BZLF1*and/or *BRLF1*(Figure [2B](#F2){ref-type="fig"}). To further confirm the MSP results and characterize the methylation status of Zp and Rp in more detail, we performed high-resolution bisulfite genome sequencing (BGS) analysis of 18 CpG sites and 20 CpG sites spanning Zp and Rp, respectively. In EBV-positive BL cell lines Real, Akata, Namalwa and Raji, dense methylation was observed at both Zp and Rp, while relatively more unmethylated alleles in Zp and Rp were detected in B95-8 and Wan cell lines which are with high level of spontaneous EBV lytic replication \[[@B27],[@B28]\]. Notably, three CpG sites (\#12-14) in Zp were always unmethylated (Figure [2C, D](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"}). These results suggest that promoter methylation is closely related to the transcriptional repression of *BZLF1*and *BRLF1*in EBV-positive cell lines.

###### 

Methylation status of Zp and Rp in EBV-associated cell lines and tumors

  ----------------------------------------------------------------------------------------------
  EBV-associated cell lines and tumors   Zp methylation status\      Rp methylation status\
                                         (Methylated CpG sites, %)   (methylated CpG sites, %)
  -------------------------------------- --------------------------- ---------------------------
  **Cell lines**                                                     

  Akata                                  67%                         59%

  B95-8                                  17%                         36%

  C666-1                                 75%                         99%

  Namalwa                                46%                         53%

  Raji                                   60%                         87%

  Rael                                   67%                         83%

  Wan                                    18%                         29%

  **Nude mice-passaged tumors**                                      

  C15                                    68%                         96%

  C18                                    56%                         59%

  **Tumors**                                                         

  NPC                                                                

  NPC1                                   58%                         97%

  NPC2                                   92%                         88%

  NPC12                                  70%                         87%

  BL                                                                 

  BL3                                    62%                         80%

  BL5                                    53%                         82%

  BL10                                   67%                         82%

  PTLD                                                               

  PTLD2                                  32%                         64%

  PTLD4a                                 44%                         85%

  PTLD8                                  22%                         70%

  PTLD10                                 47%                         73%

  PTLD19                                 53%                         80%

  PTLD20                                 75%                         80%
  ----------------------------------------------------------------------------------------------

Zp and Rp methylation in EBV-positive tumors
--------------------------------------------

EBV-positive tumors of epithelial or lymphoid origin including NPC, BL and PTLD samples, as well as two nude mice-passaged undifferentiated

NPC tumors (C15 and C18) were studied. MSP analysis showed that Zp and Rp methylation was detected in virtually all 38 NPC tumors, with unmethylated Zp and Rp only detected in rare cases (Figure [3A, B](#F3){ref-type="fig"}), well correlated with the general silencing of *BZLF1*and *BRLF1*in NPC (Figure [3C](#F3){ref-type="fig"}).

![**(A, B, C) Representative MSP analysis of Zp and Rp methylation**. M, methylated; U, unmethylated. NPC, nasopharyngeal carcinoma. (D) RT-PCR analysis of *BZLF1*and *BRLF1*expression in primary NPC.](1471-2407-12-125-3){#F3}

We further studied the detailed methylation profiles of Zp and Rp by BGS in EBV-positive tumors. Results revealed that both Zp and Rp were heavily methylated in all studied samples, but relatively more unmethylated alleles in Zp were observed in PTLD patients (Figure [4A, B](#F4){ref-type="fig"}). Again, we observed that the three CpG sites (\#12-14) in Zp were unmethylated in virtually all studied tumors (Figure [4A](#F4){ref-type="fig"}). These results are summarized in Table [2](#T2){ref-type="table"}.

![**(A, B) Methylation profiling of Zp and Rp of multiple EBV-associated tumors**. NPC, nasopharyngeal carcinoma; BL, Burkitt lymphoma; PTLD, posttransplant lymphoproliferative disease. Circles, CpG sites analyzed; row of circles, an individual promoter allele sequenced; Filled circle, methylated; empty circle, unmethylated. \"x\" circle, CpG site abolished by sequence variation or undetermined methylation status due to unconverted C in nearby CpN site.](1471-2407-12-125-4){#F4}

Restoration of *BZLF1*and *BRLF1*expression by demethylation in EBV-positive cell lines
---------------------------------------------------------------------------------------

To determine whether methylation directly mediates the transcriptional repression of *BZLF1*and *BRLF1*, Rael, NK-YS and C666-1 were treated with 5-aza-2\'-deoxycytidine (5-aza-dC), a DNA methyltransferase inhibitor. Rael treated with 5-aza-dC at different concentrations (0.005, 0.015, 0.03, 0.06, 0.5 and 1 μM) for 72 h. MSP analysis showed that unmethylated Rp and Zp alleles were increased in a dose-dependent manner, with significant demethylation of Rp and Zp observed by treatment with 1 μM 5-aza-dC. Subsequently, 1 μM of 5-aza-dC was chosen to evaluate the demethylation of Zp and Rp for different indicated times (5 h, 24 h, 30 h, 48 h) in Rael cell line. It was found that both Zp and Rp were demethylated in a time-dependent manner (Figure [5A, B](#F5){ref-type="fig"}). Similarly, NK-YS and C666-1 cells treated with 5-aza-dC at different concentrations showed obvious demethylation of Zp and Rp, compared with untreated cells (Figure [5C, D](#F5){ref-type="fig"}). Concomitantly, Zp and Rp alleles were partially demethylated after 5-aza-dC treatment by high-resolution BGS analysis (Figure [5E, F](#F5){ref-type="fig"}, Table [2](#T2){ref-type="table"}),

![**(A-D) Pharmacologic demethylation with 5-aza-dC at indicated concentrations and time points analyzed by MSP in Rael, NK-YS and C666-1 cell lines**. Each bottom panel is the plotted densitometry ratios as % of methylation (U/U + M) of Zp and Rp. M, methylated; U, unmethylated. (E, F). Detailed BGS analysis of demethylation after 5-aza-dC treatment in Rael and C666-1 cell lines. \"x\" circle, CpG site abolished by sequence variation or undetermined methylation status due to an unconverted C in nearby CpN site.](1471-2407-12-125-5){#F5}

We further found that after 5-aza-dC demethylation or combined with the histone deacetylase inhibitor (HDACi) trichostatin A (TSA) treatment, the expression of *BZLF1*and *BRLF1*was dramatically increased in EBV-positive epithelial cell lines, as measured by RT-PCR, along with obviously induced expression of early lytic gene *BHRF1*and late lytic gene *BLLF1*(Figure [6A, B, C](#F6){ref-type="fig"}), suggesting the initiation of EBV-lytic cascade by DNA demethylation. We further performed the profiling of Rp methylation after 5-aza-dC treatment with TSA in YCCEL1 and SNU719. Detailed mapping of Rp by BGS analysis revealed Rp demethylation after 5-aza-dC treatment combined with TSA as expected, while the critical sites of Rp (CpG site \#13-15) still maintain partially methylated required for Zta activation (Figure [6D](#F6){ref-type="fig"}), indicating epigenetic-mediated silencing of *BZLF1*and *BRLF1*in EBV-associated epithelial tumors.

![**(A, B, C) Restoration of *BZLF1*and *BRLF1*expression, as well as *BHRF1*(lytic) and *BLLF1*by 5-aza-dC treatment or combined with HDACi-TSA analyzed by RT-PCR**. *BART*as an internal control for EBV latent gene expression. (D) Methylation profiling of Rp by detailed BGS analysis of demethylation after 5-aza-dC treatment with TSA in YCCEL1 and SNU719 cell lines.](1471-2407-12-125-6){#F6}

Discussion
==========

This study characterized the CpG methylation profiles of EBV immediate-early lytic promoters Zp and Rp in cell lines and tumors of epithelial or lymphoid origin, and further evaluated the reactivation of *BZLF1*and *BRLF1*by demethylation treatment. We found that Zp and Rp were frequently methylated in all EBV-positive cell lines and tumors, whereas unmethylated Zp and Rp were mainly present in EBV-positive cell lines with lytic activities, along with the expression of *BZLF1*and *BRFL1*. We did not observe major difference in Zp and Rp methylation in cell lines/or tumors of epithelial, NK- or B-cell origin.

We also demonstrated that demethylation of Zp and Rp by treatment with 5-aza-dC alone or combined with TSA resulted in the re-expression of *BZLF1*and *BRLF1*and activation of EBV lytic cycle. It has been identified that DNA synthesis inhibitors have no effect on DNA methylation by using four different inhibitors of DNA replication \[[@B29]\]. Although DNA synthesis inhibitors will delay some of the cytosine methylation, all delayed DNA methylation will be finally completed prior to the subsequent S phase. Thus, in our study, DNA methylation inhibitors are mainly responsible for Zp and Rp demethylation and initiation of lytic cascade, while other events indirectly leading to EBV reactivation also cannot be ruled out.

In EBV-positive cell lines except for B95-8, Wan and AG876, only very few % of cells or no cell undergoing spontaneous lytic infection without much lytic virion DNA, thus the methylation status of Zp and Rp detected represents the latent viral genome but not the virion genome, while in B95-8, Wan and AG876 cell lines with significant % of cells undergoing spontaneous lytic infection, the methylation status detected probably represents both latent and viral genomes (Figure [2C, D](#F2){ref-type="fig"}). Similarly, in EBV-positive tumors with rare cell undergoing spontaneous lytic infection, methylation status represents the latent genome \[[@B1]\]. In our study, lower level of methylation was only observed in B95-8 and Wan cell lines, but not in other EBV-positive cell lines and primary tumors, consistent with the high level of spontaneous EBV lytic replication only in B95-8 and Wan.

The existence of a small proportion of cells expressing viral lytic genes is essential for the success maintenance of EBV latency in host cells with a highly methylated viral genome \[[@B1],[@B3]\]. As viral transactivator proteins, Zta is unique to initiate the entire EBV lytic cascade by transactivating a series of lytic gene promoters, but Rta appears to be more effective in epithelial cells \[[@B30],[@B31]\]. Increased evidences have shown that Zta initiates EBV lytic infection mainly from a methylated viral genome, whereas Rta initiates lytic infection mainly from an unmethylated genome \[[@B15],[@B16],[@B32],[@B33]\]. Rp methylation inhibits Rta expression, however it enhances the ability of Zta to activate Rp \[[@B16]\]. In line with reported studies, we found that either the Rp-ZRE2 (CpG site \#13-14) or/and the ZRE3 (CpG site \#15) were heavily methylated in virtually all EBV-positive BL, LCL and NPC cell lines and tumors, but less methylated in Wan and B95-8 cells with basal lytic activity. A CpG methylation-free zone (three CpG sites \#12-14) in Zp, located in regulatory elements YY1 and E2-2, is possibly responsible for the initial activation of *BZLF1*. Thus, Zp and Rp are regulated by both CpG methylation and cellular transcription factors, indicating the complexity of the regulation of *BZLF1*and *BRLF1*in EBV-associated tumors \[[@B34]\].

DNA methylation plays a crucial role in allowing EBV to escape from the detection of host immune system. Conversely, pharmacologic reversal of viral gene methylation and activation of gene expression would resensitize host\'s immune surveillance or enhance its response to immunogenic viral antigens \[[@B10]\]. The efficacy of DNA methyltransferase inhibitors in hematologic diseases, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, has been successfully evaluated by multiple clinical trials \[[@B35]-[@B37]\]. 5-azacytidine has been now approved as the first-line treatment of high-risk MDS \[[@B38],[@B39]\]. Our group has firstly reported the achievement of successful demethylation of EBV viral antigen promoters including Cp, Wp, LMP1p, Zp and Rp, in NPC patients with azacitidine treatment \[[@B1],[@B10]-[@B12]\]. When combined with other chemotherapy drugs and histone deacetylase inhibitors (HDACi), DNMT inhibitors should have even brighter perspective in the therapeutics of EBV-associated tumors (Figure [7](#F7){ref-type="fig"}) \[[@B40]\].

![**Model of demethylation inducing EBV lytic cascade in EBV-positive tumor cells**.](1471-2407-12-125-7){#F7}

Conclusions
===========

Collectively, our study found that frequent silencing of *BZLF1*and *BRLF1*by hypermethylation of Zp and Rp could be reactivated by demethylation agent, resulting in the initiation of the EBV lytic cascade in EBV-associated tumors. Our study helps to understand epigenetics-related EBV pathogenesis and further develop target therapy for EBV-associated tumors.
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